Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Subjects must have confirmed diagnosis of unresectable hepatocellular carcinoma (HCC) categorized to stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system with any of following criteria: 1) Lesion limited to a single lobe that is within the radiotherapy field, 2) Lesion not limited to a single lobe, but the lesion that is not within the radiotherapy field can be controlled by transarterial chemoembolization or radiofrequency ablation, 3) Presence of metastatic lesions that measure \< 1.0 cm in the long axis, 4) The lesion can be accurately measured in at least one dimension as ≥ 1.0 cm * Males or females aged at least 20 years and below 76 years * Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 or 1 * Adequate liver function, defined as: 1) Child-Pugh score ≤ 7, 2) Bilirubin ≤ 3.0 mg/dL * Adequate bone marrow function, defined as: 1) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, 2) White blood cell count (WBC) ≥ 4.0 × 109/L, 3) Platelet count ≥ 60 × 109/L * Adequate renal function, defined as serum creatinine \< 2.0 mg/dL * Subjects with hepatitis B virus (HBV)-related HCC must have adequately controlled HBV replication status * Adequate blood coagulation factors, defined as international normalized ratio (INR) ≤ 2.3 * Provide written informed consent * Willing and able to comply with all aspects of the protocol Exclusion Criteria: * Significant liver function impairment, defined as bilirubin \> 3.0 mg/dL or uncontrol…